EE200200248A - Adenosiini retseptori antagonistid ja nende valmistamise ja kasutamise meetodid - Google Patents

Adenosiini retseptori antagonistid ja nende valmistamise ja kasutamise meetodid

Info

Publication number
EE200200248A
EE200200248A EEP200200248A EEP200200248A EE200200248A EE 200200248 A EE200200248 A EE 200200248A EE P200200248 A EEP200200248 A EE P200200248A EE P200200248 A EEP200200248 A EE P200200248A EE 200200248 A EE200200248 A EE 200200248A
Authority
EE
Estonia
Prior art keywords
preparation
methods
receptor antagonists
adenosine receptor
adenosine
Prior art date
Application number
EEP200200248A
Other languages
English (en)
Estonian (et)
Inventor
Lee Ensinger Carol
E. Dowling James
Kumaravel Gnanasambandam
C. Petter Russell
Original Assignee
Biogen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen, Inc. filed Critical Biogen, Inc.
Publication of EE200200248A publication Critical patent/EE200200248A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12Antidiuretics, e.g. drugs for diabetes insipidus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
EEP200200248A 1999-11-12 2000-11-13 Adenosiini retseptori antagonistid ja nende valmistamise ja kasutamise meetodid EE200200248A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16528399P 1999-11-12 1999-11-12
PCT/US2000/031100 WO2001034604A2 (en) 1999-11-12 2000-11-13 Adenosine receptor antagonists and methods of making and using the same

Publications (1)

Publication Number Publication Date
EE200200248A true EE200200248A (et) 2003-06-16

Family

ID=22598257

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200248A EE200200248A (et) 1999-11-12 2000-11-13 Adenosiini retseptori antagonistid ja nende valmistamise ja kasutamise meetodid

Country Status (33)

Country Link
US (4) US6605600B1 (cs)
EP (2) EP1230241B1 (cs)
JP (1) JP2003513976A (cs)
KR (1) KR100845488B1 (cs)
CN (1) CN1187354C (cs)
AT (1) ATE353328T1 (cs)
AU (1) AU784528B2 (cs)
BG (1) BG106693A (cs)
BR (1) BR0015540A (cs)
CA (1) CA2390590C (cs)
CY (1) CY1106560T1 (cs)
CZ (1) CZ20021615A3 (cs)
DE (1) DE60033310T2 (cs)
DK (1) DK1230241T3 (cs)
EA (1) EA010260B1 (cs)
EE (1) EE200200248A (cs)
ES (1) ES2281367T3 (cs)
GE (1) GEP20043267B (cs)
HK (1) HK1049153B (cs)
HU (1) HUP0203371A3 (cs)
IL (1) IL149486A0 (cs)
IS (1) IS6380A (cs)
MX (1) MXPA02004795A (cs)
NO (1) NO20022237L (cs)
NZ (2) NZ519427A (cs)
PL (1) PL198156B1 (cs)
PT (1) PT1230241E (cs)
SK (1) SK6622002A3 (cs)
TR (1) TR200301062T2 (cs)
UA (1) UA77937C2 (cs)
WO (1) WO2001034604A2 (cs)
YU (1) YU33702A (cs)
ZA (1) ZA200203702B (cs)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI229674B (en) 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
CZ20021615A3 (cs) * 1999-11-12 2002-08-14 Biogen, Inc. Antagonisty adenosinového receptoru, způsoby jejich přípravy a způsoby jejich pouľití
ES2323357T3 (es) * 1999-11-12 2009-07-14 Biogen Idec Ma Inc. Policicloalquilpurinas como antagonistas del receptor de adenosina.
BR0312137A (pt) * 2002-06-12 2005-04-05 Mcw Res Found Inc Processo de tratamento de dano de reperfusão de isquemia usando antagonistas de receptor de adenosina
WO2004009594A2 (en) * 2002-07-19 2004-01-29 Aryx Therapeutics Xanthine derivatives having adenosine a1-receptor antagonist properties
US20040229901A1 (en) * 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
CA2522323C (en) * 2003-04-14 2009-09-15 Pfizer Products Inc. 3-azabicyclo[3.2.1]octane derivatives as opioid receptor ligands
BRPI0409699A (pt) 2003-04-25 2006-04-18 Novacardia Inc métodos de indução do efeito diurético, de indução, manutenção ou restauração do efeito diurético de diurético não modificador de adenosina, de manutenção, restauração ou melhoria da função renal em paciente, de indução de diurese, de prevenção do inìcio de deficiência renal em paciente com sobrecarga de fluidos ou chf, de tratamento de paciente que sofre de chf e de melhoria dos resultados globais da saúde, composição farmacêutica e seus usos
US7247639B2 (en) * 2003-06-06 2007-07-24 Endacea, Inc. A1 adenosine receptor antagonists
CA2644996A1 (en) * 2006-03-02 2007-09-13 Cv Therapeutics, Inc. A2a adenosine receptor antagonists
CN101420958A (zh) * 2006-04-06 2009-04-29 挪瓦卡尔迪阿公司 共投与腺苷a1受体拮抗剂和抗惊厥药
HRP20110917T1 (hr) 2006-05-19 2012-03-31 Abbott Laboratories Derivati azabicikličkih alkana supstituirani fuzioniranim bicikloheterociklima aktivni u središnjem živčanom sustavu
EP2035009A1 (en) * 2006-06-16 2009-03-18 Novacardia, Inc. Prolonged improvement of renal function comprising infrequent administration of an aa1ra
WO2008121893A1 (en) * 2007-03-29 2008-10-09 Novacardia, Inc. Methods of treating heart failure and renal dysfunction in individuals with an adenosine a1 receptor antagonist
WO2008121882A1 (en) * 2007-03-29 2008-10-09 Novacardia, Inc. Improved methods of administration of adenosine a1 receptor antagonists
US20090228097A1 (en) * 2008-03-07 2009-09-10 Abbott Cardiovascular Systems Inc. A1 Adenosine Receptor Antagonist-Coated Implantable Medical Device
CN114790164B (zh) 2021-08-13 2022-12-27 苏州璞正医药有限公司 一种取代的异吲哚啉-1,3-二酮类pde4抑制剂及其药物用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3155664A (en) * 1959-11-13 1964-11-03 Endo Lab Derivatives of theophylline
DE3843117A1 (de) * 1988-12-22 1990-06-28 Boehringer Ingelheim Kg Neue xanthinderivate mit adenosin-antagonistischer wirkung
JPH06102662B2 (ja) * 1989-09-01 1994-12-14 協和醗酵工業株式会社 キサンチン誘導体
US5290782A (en) 1989-09-01 1994-03-01 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
US5270316A (en) 1989-10-20 1993-12-14 Kyowa Hakko Kogyo Co., Ltd. Condensed purine derivatives
DE4019892A1 (de) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
CA2061544A1 (en) 1991-02-25 1992-08-26 Fumio Suzuki Xanthine compounds
EP0541120B1 (en) 1991-11-08 1999-05-26 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives for the treatment of dementia
EP0556778A3 (en) 1992-02-17 1993-11-24 Kyowa Hakko Kogyo Kk Xanthine derivatives
US5342841A (en) 1992-03-12 1994-08-30 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
TW252044B (cs) 1992-08-10 1995-07-21 Boehringer Ingelheim Kg
WO1994016702A1 (en) 1993-01-26 1994-08-04 Kyowa Hakko Kogyo Co., Ltd. Remedy for irregular bowel movement
JP3729874B2 (ja) * 1993-04-07 2005-12-21 協和醗酵工業株式会社 キサンチン誘導体
US5395836A (en) 1993-04-07 1995-03-07 Kyowa Hakko Kogyo Co., Ltd. 8-tricycloalkyl xanthine derivatives
US5446046A (en) * 1993-10-28 1995-08-29 University Of Florida Research Foundation A1 adenosine receptor agonists and antagonists as diuretics
WO1998057644A1 (fr) 1997-06-16 1998-12-23 Kyowa Hakko Kogyo Co., Ltd. Agent de prevention et remede contre la nephropathie induite par les medicaments
WO1998057645A1 (fr) 1997-06-16 1998-12-23 Kyowa Hakko Kogyo Co., Ltd. Medicament contre l'oedeme hepatique
DE19816857A1 (de) * 1998-04-16 1999-10-21 Boehringer Ingelheim Pharma Neue unsymmetrisch substituierte Xanthin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP0955301A3 (en) * 1998-04-27 2001-04-18 Pfizer Products Inc. 7-aza-bicyclo[2.2.1]-heptane derivatives, their preparation and use according to their affinity for neuronal nicotinic acetylcholine receptors
ES2284256T3 (es) 1998-07-02 2007-11-01 Kyowa Hakko Kogyo Co., Ltd. Medicamentos para la diabetes.
CZ20021615A3 (cs) * 1999-11-12 2002-08-14 Biogen, Inc. Antagonisty adenosinového receptoru, způsoby jejich přípravy a způsoby jejich pouľití
ES2323357T3 (es) * 1999-11-12 2009-07-14 Biogen Idec Ma Inc. Policicloalquilpurinas como antagonistas del receptor de adenosina.

Also Published As

Publication number Publication date
US20050222179A1 (en) 2005-10-06
CN1399636A (zh) 2003-02-26
EP1230241A2 (en) 2002-08-14
IS6380A (is) 2002-05-10
CA2390590A1 (en) 2001-05-17
DE60033310D1 (de) 2007-03-22
NZ527918A (en) 2005-05-27
BG106693A (bg) 2003-01-31
DE60033310T2 (de) 2007-11-22
WO2001034604A2 (en) 2001-05-17
HK1049153B (en) 2007-09-28
BR0015540A (pt) 2002-07-23
EA200200562A1 (ru) 2002-10-31
GEP20043267B (en) 2004-06-25
PL356044A1 (en) 2004-06-14
NO20022237D0 (no) 2002-05-10
TR200301062T2 (tr) 2003-09-22
AU784528B2 (en) 2006-04-27
WO2001034604A3 (en) 2002-01-10
CA2390590C (en) 2010-03-16
NZ519427A (en) 2003-08-29
EP1775297A2 (en) 2007-04-18
EP1775297A3 (en) 2008-12-03
HUP0203371A3 (en) 2005-02-28
PL198156B1 (pl) 2008-05-30
PT1230241E (pt) 2007-05-31
AU2042101A (en) 2001-06-06
US20030225038A1 (en) 2003-12-04
CZ20021615A3 (cs) 2002-08-14
EA010260B1 (ru) 2008-06-30
YU33702A (sh) 2005-03-15
US20080004293A1 (en) 2008-01-03
IL149486A0 (en) 2002-11-10
SK6622002A3 (en) 2003-02-04
ZA200203702B (en) 2003-10-29
MXPA02004795A (es) 2005-07-01
US6605600B1 (en) 2003-08-12
CN1187354C (zh) 2005-02-02
HK1049153A1 (en) 2003-05-02
ES2281367T3 (es) 2007-10-01
KR100845488B1 (ko) 2008-07-10
NO20022237L (no) 2002-07-12
EP1230241B1 (en) 2007-02-07
DK1230241T3 (da) 2007-06-04
ATE353328T1 (de) 2007-02-15
CY1106560T1 (el) 2012-01-25
KR20020049043A (ko) 2002-06-24
HUP0203371A2 (hu) 2003-02-28
UA77937C2 (en) 2007-02-15
JP2003513976A (ja) 2003-04-15

Similar Documents

Publication Publication Date Title
CY1110512T1 (el) Πολυκυκλοαλκυλοπουρινες ως ανταγωνιστες υποδοχεων αδενοσινης
CY1106560T1 (el) Ανταγωνιστες υποδοχεα αδενοσινης και μεθοδοι κατασκευης και χρησης αυτων
WO1997020823A3 (en) 2-amino quinazoline derivatives as npy receptor antagonists
WO2003048164A3 (en) Adenosine a2a receptor antagonists
IL147977A0 (en) Substituted 1,5-dihydropyrrol-2-on derivatives as nmda receptor antagonists for the treatment of pain
CA2094702A1 (en) Substituted tetrahydropyridines and hydroxypiperidines as central nervous system agents
CA2275686A1 (en) Isoquinolinamine and phthalazinamine derivatives which interact with crf receptors
ATE256126T1 (de) 5-heteroatom-alkyl substituierte 3-oxo-pyrido(1,2-a)benzimidazol-4-carboxamid derivate zur behandlung zentral nervöser system störungen
NZ533358A (en) 3,4-Dihydro-1H-isoquinolin-2-yl-derivatives for use as NK2 receptor antagonists
PT889044E (pt) Derivados do 5-(heteroaril)alquil-3-oxo-pirido-(1,2-a)benzimidazole-4-carboxamida (pbi) uteis no tratamento de perturbacoes do sistema nervoso central
ATE321044T1 (de) C-6 ringsubstituierte pyrido(1,2- a)benzimidazolderivate zur behandlung von störungen des zentralen nervensystems
NO20053612L (no) 1,2,4-triaminobenzenderivater nyttige for behandling av forstyrrelser i sentralnervesystemet
SI1200402T1 (sl) Substituirani 1,5-dihidropirol-2-on-derivati, ucinkoviti kot antagonisti NMDA-receptorja za tretiranje bolecinskih stanj

Legal Events

Date Code Title Description
HC1A Change of owner name